News

Human Life CORD Japan Inc. (President and CEO: Masamitsu Harata, Headquarters: Chuo-ku, Tokyo, Japan, hereinafter referred to as “HLC”) and New York Blood Center Enterprises (President and CEO: Christopher D. Hillyer, MD, Headquarters: New York, USA, hereinafter “NYBCe”) have entered into a non-binding Memorandum of Understanding (MOU) to negotiate in good faith toward a definitive contract manufacturing agreement, in which NYBCe will serve as the exclusive contract development and manufacturing organization (CDMO) for HLC in the United States. Through this collaboration, NYBCe will produce clinical-grade umbilical cord-derived mesenchymal stromal cell (UC-MSC) products for use in clinical trials aligned with HLC’s therapeutic pipeline.

Under the MOU, NYBCe is undertaking a facility buildout at its Rye, NY site.
As part of this collaboration, HLC acknowledges the importance of securing cleanroom capacity at this facility and commits to utilizing such capacity.

The facility will operate in accordance with industry best practices for cGMP-compliant manufacturing and will meet FDA and other regulatory standards to support clinical stage development and IND-related applications.

Both parties will continue discussions toward a definitive agreement aimed at establishing a long-term manufacturing and regulatory framework to accelerate HLC’s global clinical strategy.
 

 
About New York Blood Center Enterprises. (NYBCe)
Founded in 1964, New York Blood Center Enterprises (NYBCe) has provided more than 60 years of lifesaving research, innovation, and impact. NYBCe is one of the largest nonprofit blood centers, spanning 17+ states and serving 75 million people. NYBCe operates Blood Bank of Delmarva, Community Blood Center of Kansas City, Connecticut Blood Center, Memorial Blood Centers, Nebraska Community Blood Bank, New Jersey Blood Services, New York Blood Center, and Rhode Island Blood Center, delivering one million blood products to 400+ U.S. hospitals annually. NYBCe additionally delivers cellular therapies, specialty pharmacy, and medical services to 200+ research, academic, and biopharmaceutical organizations. NYBCe’s Lindsley F. Kimball Research Institute is a leader in hematology and transfusion medicine research, dedicated to the study, prevention, treatment and cure of bloodborne and blood-related diseases. NYBCe is a vital community lifeline dedicated to helping patients and advancing global public health. To learn more, visit nybce.org Connect with us on Facebook, X, Instagram, and LinkedIn.
 

 
[Press Release PDF] HLC & NBC Sign MOU to Establish U.S. Manufacturing Capacity for Advanced Cell Therapies
 
[Contact for Media Inquiries]
Public Relations, Human Life CORD Japan Inc.
Attn: Yuki Hayashi
TEL: +81-80-4671-0405
Email: info@humanlifecord.com